Ningbo Cixing (300307.SZ) announced an expected increase, with an estimated net profit of 285 million to 330 million yuan for the year 2024, a year-on-year growth of 149.84% to 189.29%.
CiXing Group (300307.SZ) released its 2024 annual performance forecast, with the company projecting that its attributable...
Ningbo Cixing (300307.SZ) released its performance forecast for the year 2024, with the company expecting a net profit attributable to shareholders of the listed company of 285 million to 330 million yuan, a year-on-year growth of 149.84% to 189.29%; after deducting non-recurring gains and losses, the net profit is expected to be 100 million to 145 million yuan, a year-on-year growth of 49.49% to 116.76%.
Related Articles
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.
CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.
On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.
CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.
On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
